We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Assay Approved as First Companion Diagnostic to Elahere for Ovarian Cancer Patients
Roche Assay Approved as First Companion Diagnostic to Elahere for Ovarian Cancer Patients
Roche’s Ventana FOLR1 assay has been approved by the FDA as the first companion diagnostic test to identify patients eligible for treatment with ImmunoGen’s Elahere (mirvetuximab soravtansine-gynx) also recently FDA approved.